Pediatrix Medical price target lowered to $16 from $18 at Truist

Truist analyst David MacDonald lowered the firm’s price target on Pediatrix Medical (MD) to $16 from $18 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm’s models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm’s expectation of a better environment, the analyst tells investors in a research note.